[go: up one dir, main page]

BR9915379A - Forma de dosagem e processo para a preparação de uma forma de dosagem - Google Patents

Forma de dosagem e processo para a preparação de uma forma de dosagem

Info

Publication number
BR9915379A
BR9915379A BR9915379-3A BR9915379A BR9915379A BR 9915379 A BR9915379 A BR 9915379A BR 9915379 A BR9915379 A BR 9915379A BR 9915379 A BR9915379 A BR 9915379A
Authority
BR
Brazil
Prior art keywords
dosage form
preparing
amifostine
amorphous
relates
Prior art date
Application number
BR9915379-3A
Other languages
English (en)
Inventor
Martin Stogniew
Javad M Zadei
Original Assignee
Us Bioscience
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Bioscience filed Critical Us Bioscience
Publication of BR9915379A publication Critical patent/BR9915379A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

"FORMA DE DOSAGEM E PROCESSO PARA A PREPARAçãO DE UMA FORMA DE DOSAGEM". A presente invenção refere-se às formas de dosagem estáveis, estéreis, adequadas para reconstituição e administração parenteral a um paciente, a citada forma de dosagem compreendendo um di-hidrogeno-fósforo-tioato de amino-alquila amorfo, e em particular amifostina. A invenção refere-se adicionalmente a um processo de preparação de uma tal forma de dosagem, que tipicamente exibe estabilidade térmica aumentada em comparação com a existente amifostina amorfa seca a vácuo.
BR9915379-3A 1998-11-16 1999-11-15 Forma de dosagem e processo para a preparação de uma forma de dosagem BR9915379A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/192,933 US6407278B2 (en) 1998-11-16 1998-11-16 Stable amorphous amifostine compositions and methods for the preparation and use of the same
PCT/US1999/027050 WO2000029025A1 (en) 1998-11-16 1999-11-15 Stable amorphous amifostine compositions and methods for the preparation and use of same

Publications (1)

Publication Number Publication Date
BR9915379A true BR9915379A (pt) 2002-01-15

Family

ID=22711626

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9915379-3A BR9915379A (pt) 1998-11-16 1999-11-15 Forma de dosagem e processo para a preparação de uma forma de dosagem

Country Status (16)

Country Link
US (1) US6407278B2 (pt)
EP (1) EP1131103A1 (pt)
JP (1) JP4703854B2 (pt)
KR (1) KR20010101015A (pt)
CN (1) CN1195549C (pt)
AU (1) AU1725500A (pt)
BR (1) BR9915379A (pt)
CA (1) CA2350815C (pt)
CZ (1) CZ20011722A3 (pt)
HK (1) HK1041639B (pt)
HU (1) HUP0104372A2 (pt)
ID (1) ID30238A (pt)
MX (1) MXPA01004867A (pt)
PL (1) PL347691A1 (pt)
SK (1) SK6672001A3 (pt)
WO (1) WO2000029025A1 (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994409A (en) * 1997-12-09 1999-11-30 U.S. Bioscience, Inc. Methods for treatment of neuro--and nephro--disorders and therapeutic toxicities using aminothiol compounds
US6384259B1 (en) * 1998-11-16 2002-05-07 Medimmune Oncology, Inc. Stable amorphous amifostine compositions and dosage form
DE10043170C2 (de) * 2000-09-01 2002-10-24 Klinge Co Chem Pharm Fab Amifostin-Monohydrat und Verfahren zu seiner Herstellung
JP2005522422A (ja) * 2002-02-01 2005-07-28 シモダ、バイオテック（プロプライエタリー）リミテッド 医薬組成物
US7629333B2 (en) * 2002-03-29 2009-12-08 Medimmune, Llc Stable amorphous amifostine compositions and methods for the preparation and use of same
US20030215394A1 (en) * 2002-05-17 2003-11-20 Short Robert E. Microparticles having a matrix interior useful for ultrasound triggered delivery of drugs into the bloodstream
SI21302A (sl) * 2002-10-11 2004-04-30 LEK farmacevtska dru�ba d.d. Stabiliziran farmacevtski izdelek z amorfno aktivno učinkovino
US20050049209A1 (en) * 2003-08-06 2005-03-03 Chen Andrew Xian Pharmaceutical compositions for delivering macrolides
WO2005046696A1 (ja) 2003-11-14 2005-05-26 Ajinomoto Co., Inc. フェニルアラニン誘導体の固体分散体または固体分散体医薬製剤
JP4526838B2 (ja) * 2004-03-04 2010-08-18 エーザイ・アール・アンド・ディー・マネジメント株式会社 配合適性試験用試料の調製方法及びそれに用いるキット
US20060121016A1 (en) * 2004-10-18 2006-06-08 Lee Raphael C Methods and compositions for treatment of free radical injury
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
US8133513B2 (en) 2006-03-23 2012-03-13 Shionogi & Co., Ltd. Solid preparation having improved solubility
US8815833B2 (en) * 2006-11-09 2014-08-26 Seidose, LLC Stable amifostine liquid concentrate
US20080253997A1 (en) * 2007-03-27 2008-10-16 Perscitus Biosciences, Llc Compositions and methods for protecting cells from toxic exposures
US20100240711A1 (en) 2007-09-21 2010-09-23 Shionogi & Co., Ltd. Solid preparation comprising npyy5 receptor antagonist
CN101347412B (zh) * 2008-09-02 2011-07-27 大连美罗药业股份有限公司 三水合氨磷汀结晶冻干制剂及其制备方法
JP5563528B2 (ja) * 2010-06-29 2014-07-30 高田製薬株式会社 ニコチン酸アミドを含有するゲムシタビン凍結乾燥製剤
CN102286019B (zh) * 2011-07-11 2014-02-05 大连美罗大药厂 二水合3-氨基丙基胺乙基硫代磷酸的制备方法
CN104744478B (zh) * 2015-03-20 2016-08-24 中国人民解放军第二军医大学 一种防治辐射损伤的化合物、单晶及其制备方法和应用
EP3330251A1 (en) * 2016-11-30 2018-06-06 Clevexel Pharma Process for the preparation of freeze-dried 2-[(3-aminopropyl)amino]ethanethiol
EP3860585A4 (en) 2018-10-01 2022-06-22 Wintermute Biomedical, Inc. Therapeutic compositions
CN110755373B (zh) * 2019-11-18 2020-09-08 扬子江药业集团广州海瑞药业有限公司 一种盐酸法舒地尔注射液药物组合物及制备方法
EP3824880A1 (en) * 2019-11-25 2021-05-26 Clevexel Pharma Freeze-dried powder containing 2-[(3-aminopropyl)amino]ethanethiol and its use for preparing a thermogel
CN116283682B (zh) * 2023-02-21 2024-08-02 梯尔希（南京）药物研发有限公司 一种同位素标记的氨磷汀代谢物的制备方法
WO2024225432A1 (ja) * 2023-04-28 2024-10-31 シード医療製薬株式会社 Ｎｍｎ凍結乾燥製剤の製造方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3892824A (en) 1968-12-16 1975-07-01 Southern Res Inst S-{107 -({107 -aminoalkylamino)alkyl dihydrogen phosphorothioates
JPS6041676B2 (ja) 1977-09-21 1985-09-18 山之内製薬株式会社 Ｓ−２−（３−アミノプロピルアミノ）エチルジハイドロジエンホスホロチオエ−ト１水和結晶の新規製法
US4424216A (en) 1979-07-31 1984-01-03 The Rockefeller University Method for the reduction of mucin viscosity
US5424471A (en) 1992-07-31 1995-06-13 U.S. Bioscience, Inc. Crystalline amifostine compositions and methods of the preparation and use of same
SG47101A1 (en) * 1992-07-31 1998-03-20 Us Bioscience Crystalline amifostine compositions and methods for the preparation and use of same
US5665760A (en) * 1995-09-18 1997-09-09 Sanofi Winthrop, Inc. Lyophilized thioxanthenone antitumor agents
JP2000509018A (ja) * 1996-03-26 2000-07-18 イーライ・リリー・アンド・カンパニー 肥満タンパク質製剤
US6051563A (en) 1997-02-12 2000-04-18 U.S. Bioscience, Inc. Methods for the administration of amifostine and related compounds
EP0979647A4 (en) * 1997-02-27 2006-07-19 Nippon Shinyaku Co Ltd FAT EMULSION FOR ORAL ADMINISTRATION

Also Published As

Publication number Publication date
MXPA01004867A (es) 2003-07-21
CA2350815A1 (en) 2000-05-25
CN1333694A (zh) 2002-01-30
HK1041639A1 (en) 2002-07-19
CZ20011722A3 (cs) 2001-10-17
CA2350815C (en) 2008-10-07
JP4703854B2 (ja) 2011-06-15
WO2000029025A1 (en) 2000-05-25
KR20010101015A (ko) 2001-11-14
EP1131103A1 (en) 2001-09-12
US20020010357A1 (en) 2002-01-24
HK1041639B (zh) 2005-09-30
JP2002529519A (ja) 2002-09-10
SK6672001A3 (en) 2001-11-06
HUP0104372A2 (hu) 2002-04-29
ID30238A (id) 2001-11-15
PL347691A1 (en) 2002-04-22
CN1195549C (zh) 2005-04-06
AU1725500A (en) 2000-06-05
US6407278B2 (en) 2002-06-18

Similar Documents

Publication Publication Date Title
BR9915379A (pt) Forma de dosagem e processo para a preparação de uma forma de dosagem
CO5050303A1 (es) Composicion farmaceutica para tratar infecciones virales y metodos para su preparacion su aplicacion
AR013742A1 (es) Metodo para el tratamiento de la hipercolesterolemia con polidialilamina no substituida
BR0112540A (pt) Peptìdios como inibidores da ns-3-serina protease do vìrus da hepatite c
BR0007781A (pt) Conjugado fisiologicamente ativo, composição, e, processo para a produção de um conjugado de peg-gcsf
PL365783A1 (en) 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives
BR0014326A (pt) Composto, medicamento, uso de compostos, e, processo para a preparação de compostos
NO20026001L (no) 3'-promedikamenter av 2'-deoksy-<Beta>-L-nukleosider
ZA200108126B (en) Pharmaceutical compounds.
BR0017030B8 (pt) derivados de tiazolilamida, processo para sua preparação, composição farmacêutica que os compreende e uso dos mesmos
ES2160046A1 (es) Derivados pentapeptidicos.
DE69905712D1 (de) Verwendung von indigoähnlichen bisindolen zur herstellung eines arzneimittels zur hemmung cyclin abhängiger kinasen
PL330407A1 (en) Substituted cyclopentane compounds useful as neuraminidaze inhibitors
BR0209845A (pt) Formas de dosagem de oxcarbazepina e processo para a preparação das mesmas
ES2067854T3 (es) Polisulfato de derivado de ciclodextrina y procedimiento para preparar el mismo.
ES2100841T3 (es) 3,9-difosfaespiroundecanos y procedimiento para preparar 3,9-difosfaespiroundecanos.
BRPI9814894A (pt) processo para a preparação de ácidos 8-metóxi-quinolonocarboxílicos.
CA2364251A1 (en) Synergistic inhibition of viral replication by long-chain hydrocarbons and nucleoside analogs
TR200001288T2 (tr) Östrojen yoksunluğu sendromunun tedavisinde faydalı 2-arilbenzo (b) tiyofenler.
PT1007055E (pt) Utilizacao de amifostina
BR9906391A (pt) "processo para a produção de n-metil pirrolidona".
ES2074721T3 (es) Derivados de ciclopentano, procedimientos para su preparacion y su utilizacion farmaceutica.
BR0012735A (pt) Preparação solida, e, processo para produzir preparações
CO5150178A1 (es) Bromohidrato de eletriptan monohidrato y procedimiento para su preparacion
AR027016A1 (es) Proceso para la estabilizacion de vino

Legal Events

Date Code Title Description
TC Change of name
TE Change of address
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PRESENTE PEDIDO DE PATENTE DE ACORDO COM ART. 8O, 13, 24 E 25 DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.